Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.Adamas Pharmaceuticals Inc is a pharmaceutical company focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. The company has developed and got approved the drug GOCOVRI.